Percutaneous Radiofrequency Ablation for Liver Tumors: Technical Tips

Department of Diagnostic and Interventional Radiology, Aichi Cancer Center Hospital, Japan

Yozo Sato, Takaaki Hasegawa, Shohei Chatani, Shinichi Murata, Yoshitaka Inaba

Abstract

Percutaneous radiofrequency ablation (RFA) has been accepted as a minimally invasive therapeutic treatment for liver malignancies. Although RFA is usually applied for the treatment of small liver tumors (<3 cm), several technical developments have expanded the use of RFA. RFA is now used for the treatment of large liver tumors, and the number of complications associated with this treatment has decreased. These refinements may ultimately lead to better long-term prognosis. Here, we review recent refinements of liver RFA and provide technical tips.

Key words: Radiofrequency ablation, Transarterial chemoembolization, Ablation zone Complications

Introduction

Percutaneous radiofrequency ablation (RFA) has been accepted as a minimally invasive therapeutic treatment for liver malignancies. An initial complete response of curative RFA in patients with localized hepatocellular carcinoma (HCC) is associated with improved survival, and an ablative margin at least ≥5 mm is important to prevent local tumor progression [1]. Therefore, complete ablation with adequate safety margin is necessary. However, previous studies have clearly shown that liver tumor size significantly affects the therapeutic response [2, 3]. Tumor location is another important factor affecting therapeutic response. Liver tumors are sometimes located in so-called “difficult locations”, for instance close to the diaphragm, large vessels, gallbladder, or gastrointestinal (GI) tracts (i.e. stomach and bowel) [4]. The ablative margin for tumors in “difficult locations” may be insufficient, resulting in incomplete ablation and possibly in subsequent severe complications.

Several methods with RFA for tumors lying near critical organs or vessels have recently been reported that achieve complete ablation and reduce complications [5-7]. Hence, this review article provides technical tips on how to enhance therapeutic effects and avoid complications due to RFA for liver tumors.

How to enhance therapeutic effects

Transarterial chemoembolization (TACE) combined with RFA

TACE is a standard treatment for unresectable HCC [8]. When TACE is combined with RFA, the following synergistic effects are anticipated in addition to direct antitumor effects of RFA [9]. Several studies examining TACE combined with RFA have been performed and discussed below.

First, a decrease in the blood flow in the liver causes expansion of the ablation zone size (heat-sink effect) [5, 10, 11]. Additionally, several techniques such as TACE, portal venous embolization, balloon occlusion of the hepatic artery, and balloon occlusion of the hepatic vein have been combined with RFA to increase ablation zone size [11-16]. RFA following TACE is the most popular combination therapy among these options [5]. In Japan, TACE using emulsion of epirubicin and iodized oil is generally performed before...
RFA [11, 14, 15, 17]. The ablation zone size can be expanded significantly when RFA is continued up to four weeks after TACE treatment [11]. Morimoto et al. compared local tumor progression in HCC tumors 3.1-5.0 cm in patients treated with RFA alone and with RFA combined with TACE. The three-year local tumor progression rate was significantly lower with combination therapy than with RFA alone, 6% vs. 39%, respectively (P = 0.012) [17]. Moreover, a randomized trial comparing RFA alone or in combination with TACE in HCC patients with tumors smaller than 7 cm showed that RFA combined with TACE was superior to RFA alone in improving overall survival and recurrence-free survival (hazard ratio [HR], 0.525; 95% confidence interval [CI], 0.335 to 0.822; P = 0.002; HR, 0.575; 95% CI, 0.374 to 0.897; P = 0.009, respectively) [18]. Yamakado et al. performed a multicenter prospective study with colorectal cancer liver metastases (CRCLM) patients and showed that combination therapy of RFA with TACE using degradable starch microspheres mixed with mitomycin C (MMC) had a strong anticancer effect due to the synergetic effect of both therapeutic modalities (Figure 1) [19].

Second, TACE combined with a radiopaque agent, such as iodized oil, enhanced visibility of the index tumor on computed tomography (CT) [9]. Ultrasound (US) and CT fluoroscopy are widely used as imaging modalities for targeting the tumor during percutaneous liver RFA [20]. Visualization of intrahepatic vessels, no radiation exposure, and the angle of electrode insertion are potential advantages of US-guided RFA. However, Rhim et al. reported that approximately 45% of small HCCs referred for possible percutaneous RFA were not conspicuous with US, which is the most common guidance tool for liver RFA [21]. Dynamic contrast-enhanced US overcomes that weakness and facilitates RFA electrode placement in hypervascular HCC, which is poorly depicted with B-mode US [22]. Additionally, CT/magnetic resonance-US (CT/MR-US) fusion imaging, which enables the synchronous display of real-time US images and cross-sectional multiplanar reconstruction CT or MR images, has been useful for RFA treatment guidance [23]. On the other hand, CT fluoroscopy-guided RFA has some specific advantages compared to US-guided RFA. CT fluoroscopy images are objective and not affected by air or bone; therefore, CT fluoroscopy enables precise targeting of liver tumors with US-invisible location [20]. Takaki et al. performed CT-guided RFA followed by intra-arterial iodized-oil injection and found that all 150 US-invisible HCCs became visible on CT fluoroscopy after iodized oil injection [24]. Recently, we conducted a prospective trial of the combination treatment of a miriplatin-iodized oil suspension injection and RFA in HCC (UMIN000011285). The miriplatin-
Figure 2. Case: Recurrent hepatocellular carcinoma (HCC)

a) MRI (arterial phase image) showing an HCC measuring 3 cm (arrow) in the posterior segment. b, c) RFA under CT-fluoroscopic guidance was performed immediately after miriplatin-iodized oil suspension injection (arrow). d) MRI (portal phase image) showing adequate ablative margin (arrow) one month after RFA.

Multiple electrode switching system

Recently, a multiple electrode switching system has been introduced [25-28] that enables the simultaneous use of up to three RF electrodes and sequentially switches the power between the RF electrodes (Figure 3). The power of each RF electrode is switched automatically from one electrode to the next when the impedance reaches 30 Ω above the baseline level or when an interval of 30 seconds is reached, resulting in a large confluent ablation zone created through thermal synergy[25]. Two prospective studies of RFA for HCCs smaller than 5 cm using the multiple electrode switching system showed similar results compared to RFA alone. The 1- and 3-year local tumor progression rates were 4% and 12%, respectively, in one study [27] and 6% and 11%, respectively, in the other[28], suggesting that RFA with multiple electrode switching system enhances the therapeutic effect.
Multibipolar radiofrequency ablation

Multibipolar RFA consists of several linear electrodes (up to six) inserted inside the tumor but also around the tumor in a sequential bipolar mode (Figure 4). Multibipolar RFA, using a no-touch concept, ensures efficient tumor ablation with very low rate of local recurrence in HCC < 5 cm. Three- and five-year local tumor progression rates were 96% and 94%, respectively [29]. Additionally, another recent study indicated multibipolar RFA for large HCC > 5 cm with an acceptable safety profile [30]. However, multibipolar RFA may be technically more complex than the commonly used monopolar RFA, because it requires linear insertion of more than one electrode.

Systemic chemotherapy

Another strategy to enhance the therapeutic effect of RFA is in combination with a multi-kinase inhibitor [31, 32]. The multi-kinase inhibitor sorafenib is the standard treatment for advanced HCC, and the utility of RFA combined with sorafenib has been reported [8]. Fukuda et al. showed that combination treatment resulted in a significantly larger ablative zone [31]. However, sorafenib alone was not effective in the adjuvant setting. A randomized trial for HCC showed that sorafenib administration following resection or ablation did not result in better survival benefit [33]. Unfortunately, studies are scant on other multi-kinase inhibitor combination strategies, therefore, data are not sufficient to allow for a conclusion on their effectiveness.

Regarding immune therapies, several recent preclinical and clinical studies have suggested that thermal ablation induces therapeutically effective systemic antitumor immune responses when appropriate immunomodulators are combined [34].

How to avoid complications

Mortality and major and minor complication rates of liver RFA have been reported at 0-1.4%, 0.9-10.0%, and 0.8-32.5%, respectively [20, 35-41]. Takaki et al. reported that major complications, such as hemorrhage, liver abscess, and injury to other structures occurred in 2.8% of patients who underwent liver RFA under CT fluoroscopic guidance [20]. Various preparation techniques to avoid such complications have been reported.

Patient selection

Appropriate patient selection for liver RFA is key to avoid...
complications. The following exclusion criteria should be applied: Eastern Cooperative Oncology Group performance status 3 or more, Child-Pugh class C, platelet count <50×10^3/μL, international normalized ratio >1.5, uncontrollable ascites, and bilioenteric anastomosis [5].

**Preparations to avoid complications**

1. **Change in body position**
   If the liver tumor is located adjacent to a nearby structure that may interfere with RFA or potentially be harmed by the procedure (e.g. GI tract), changing body position may help to avoid injury (**Figure 5**). This method is non-invasive and simple to implement.

2. **GI decompression**
   GI tract decompression is a basic preparation technique when the liver tumor is located adjacent to the stomach. Gastric decompression with a nasogastric tube is useful to avoid gastric injury. Although infrequent, intestinal perforation can cause mortality. Liver RFA of a subcapsular mass within 1 cm of the adjacent bowel loops should be carefully performed and followed up closely (**Figure 6**)[40]. In addition, gallbladder needle decompression may be useful to avoid perforation of the gallbladder when the liver tumor is located nearby [42].

3. **Transcatheter cooling of the biliary tract**
   In tumors located nearby the liver hilum or gallbladder, injury of the bile duct is a possible complication. Transcatheter cooling of the intrahepatic bile duct via endoscopic nasobiliary drainage tube has been reported [43]. In this report, injection (1 ml/sec) and subsequent drainage (5 ml/sec)
Interventional Radiology 2020; 5: 50-57

Figure 7. Case: Recurrent HCC after extended right hepatectomy (courtesy of Dr. Haruyuki Takaki)

a) Plain CT after iodized oil injection showing an HCC with iodized-oil accumulation (arrow) adjacent to the colon (star). b) Hydrodissection was performed to separate the target tumor (arrow) from the colon (star). c) RFA under CT-fluoroscopic guidance was performed immediately after hydrodissection (star: colon). d) Contrast-enhanced CT showed clear ablative margin surrounding the tumor (arrow).

of cooled saline were applied repeatedly during the procedure.

4. Hydrodissection

Hydrodissection is a well-established thermo-protective technique, in which fluid is injected to separate the tumor from nearby structures [9, 44].

Mixing of the injected fluid with an iodinated contrast agent improves visibility of the injected fluid and demarcation of nearby structures (Figure 7). Campbell et al. suggested that a 1:50 ratio of iohexol (300 mg/mL) in saline or 5% dextrose in water are optimal solutions for increased visibility on CT without introducing streaking artifacts [45]. However, the injected fluid occasionally leaks from the ideal position and in these situations, use of hyaluronic acid gel may be helpful because of its high viscosity [46]. Recently, hydrodissection of the retrohepatic space in tumors close to inferior vena cava (IVC) and the ostia of the hepatic veins (HV) was reported [47]. A safe distance between the tumor and major veins using hydrodissection could theoretically minimize the heat-sink effect generated by the IVC/HV. Hence, this technique could reduce not only the risk of non-target injury, but also of the heat-sink effect.

5. Balloon catheter interposition

When the previously described methods cannot be implemented, placement of a balloon catheter between the target tumor and nearby structures appears to be a practical, safe, and effective technique to separate the tumor from nearby structures [48].

6. Transarterial embolization

Transarterial embolization before RFA reduces the incidence of hemorrhagic complications by reducing the arterial blood flow [9]. Hemorrhage is one of the most serious complications after liver RFA, with a frequency between 1.5-8.1% [20, 49]. Takaki et al. have shown that arterial embolization was a significant independent factor for reducing the risk of major hemorrhage during RFA for liver tumors (p < 0.01; odds ratio, 4.3; 95% CI, 1.5-12.7) [20]. However, a recent case report revealed formation of a pseudoaneurysm of
the hepatic artery near the ablated area, due to a late complication of infection three years post-TACE and RFA for HCC [50]. Therefore, the risk of hemorrhagic complications should be considered, even several years after RFA, especially when the ablated area is located near the hepatic artery.

Conclusions

The above techniques can be applied alone or in combination. Development of novel techniques and the advancement of technology can further reduce the number and severity of complications associated with RFA treatment and potentially improve local control of liver tumors, which ultimately will result in longer survival rates for patients who receive this treatment.

Acknowledgement: We thank Haruyuki Takaki, MD and Koichiro Yamakado, MD as the collaborators of this manuscript.

Conflict of interest: The authors declare that they have no conflict of interest.

Disclaimer: Takaaki Hasegawa and Yoshitaka Inaba are the Editorial Board members of Interventional Radiology. They were not involved in the peer-review or decision-making process for this paper.

References

1. Takahashi S, Kudo M, Chung H, Inoue T, Ishikawa E, Kitai S, et al. Initial treatment response is essential to improve survival in patients with hepatocellular carcinoma who underwent curative radiofrequency ablation therapy. Oncology 2007; 72 Suppl 1: 98-103.
2. Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazelle GS. Small hepatocellular carcinoma: treatment with radiofrequency ablation versus ethanol injection. Radiology 1999; 210: 655-661.
3. Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Ierase T, Solbiati L, et al. Hepatocellular carcinoma: radiofrequency ablation of medium and large lesions. Radiology 2000; 214: 761-768.
4. Yang W, Yan K, Wu GX, Wu W, Fu Y, Lee JC, et al. Radiofrequency ablation of hepatocellular carcinoma in difficult locations: Strategies and long-term outcomes. World J Gastroenterol 2015; 21: 1554-1566.
5. Yamakado K, Takaki H, Nakatsuka A, Yamakana T, Fujimori M, Hasegawa T, et al. Radiofrequency ablation for hepatocellular carcinoma. Gastrointest Interv 2014; 3: 35-39.
6. Tsoumakidou G, Buy X, Garion J, Enescu J, Gangi A. Percutaneous thermal ablation: how to protect the surrounding organs. Tech Vasc Inter Vasc Radiol 2011; 14: 170-176. doi: 10.1053/j.tvir.2011.02.009.
7. Lewis AR, Padula CA, McKinney JM, Toskich BB. Ablation plus transarterial embolic therapy for hepatocellular carcinoma larger than 3 cm: science, evidence, and future directions. Semin Interv Radiol 2019; 36: 303-309.
8. Cassier PA, Fumagalli E, Rutkowski P, Schöffski P, Van Glabbeke M, Debire-Rychter M, et al. European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-943.
9. Miyazaki M, Iuchi T, Takaki H, Yamanaka T, Tamura Y, Tokue H, et al. Ablation protocols and ancillary procedures in tumor ablation therapy: consensus from Japanese experts. Jpn J Radiol 2016; 34: 647-656.
10. Morimoto M1, Numata K, Nozawa A, Kondo M, Nozaki A, Nakano M, et al. Radiofrequency ablation of the liver: extended effect of transcatheter arterial embolization with iodized oil and gelatin sponge on histopathologic changes during follow-up in a pig model. J Vasc Inter Radiol 2010; 21: 1716-1724. doi: 10.1016/j.jvir.2010.06.020.
11. Yamanaka T, Yamakado K, Takaki H, Nakatsuka A, Shiraki K, Hasegawa H, et al. Ablative zone size created by radiofrequency ablation with and without chemoembolization in small hepatocellular carcinomas. Jpn J Radiol 2012; 30: 553-559.
12. Goldberg SN, Kamel IR, Kruskal JB, Reynolds K, Monsky WL, Stuart KE, et al. Radiofrequency ablation of hepatic tumors: increased tumor destruction with adjuvant liposomal doxorubicin therapy. AJR Am J Roentgenol 2002; 179: 93-101.
13. Kobayashi M, Ikeda K, Kawamura Y, Hosaka T, Szezaki H, Yatsui H, et al. Randomized controlled trial for the efficacy of hepatic arterial occlusion during radiofrequency ablation for small hepatocellular carcinoma--direct ablative effects and a long-term outcome. Liver Int 2007; 27: 353-359.
14. Yamakado K, Nakatsuka A, Takaki H, Yokoi H, Usui M, Sakurai H, et al. Early stage hepatocellular carcinoma: radiofrequency ablation combined with chemoembolization versus hepatectomy. Radiology 2008; 247: 260-266.
15. Takaki H, Yamakado K, Uraki J, Nakatsuka A, Fuke H, Yamamoto N, et al. Radiofrequency ablation combined with chemoembolization for the treatment of hepatocellular carcinomas larger than 5 cm. J Vasc Interv Radiol 2009; 20: 217-224.
16. de Baere T, Deschamps F, Briggs P, Dromain C, Boige V, Hechelhammer L, et al. Hepatic malignancies: percutaneous radiofrequency ablation during percutaneous portal or hepatic vein occlusion. Radiology 2008; 248: 1056-1066.
17. Morimoto M, Numata K, Kondou M, Nozaki A, Morita S, Tanaka K. Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. Cancer 2010; 116: 5452-5460. doi: 10.1002/cncr.25314.
18. Peng ZW1, Zhang YJ, Chen MS, Xu L, Liang HH, Lin XJ, et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol 2013; 31: 426-432. doi: 10.1200/JCO.2012.42.9936.
19. Yamakado K, Inaba Y, Sato Y, Yasumoto T, Hayashi S, Yamanaka T, et al. Radiofrequency ablation combined with hepatic arterial chemoembolization using degradable starch microsphere mixed with mitomycin C for the treatment of liver metastasis from colorectal cancer: a prospective multicenter study. Cardiovasc Intervent Radiol 2017; 40: 560-567.
20. Takaki H, Yamakado K, Nakatsuka A, Yamada T, Shiraki K, Takei Y, et al. Frequency of and risk factors for complications after liver radiofrequency ablation under CT fluoroscopic guidance in 1500 sessions: single-center experience. AJR Am J Roentgenol 2013; 200: 658-664. doi: 10.2214/AJR.12.8691.
21. Rhim H, Lee MH, Kim YS, Choi D, Lee WJ, Lim HK. Planning sonography to assess the feasibility of percutaneous radiofrequency ablation of hepatocellular carcinomas. AJR Am J Roentgenol 2008; 190: 1324-1330.
22. Minami Y1, Kudo M. Review of dynamic contrast-enhanced ultra-
sound guidance in ablation therapy for hepatocellular carcinoma. World J Gastroenterol 2011; 17: 4952-4959.

23. Makino Y, Imai Y, Igura T, Kogita S, Sawai Y, Fukuda K, et al. Feasibility of extracted-overlay fusion imaging for intraoperative treatment evaluation of radiofrequency ablation for hepatocellular carcinoma. Liver Cancer 2016; 5: 269-279.

24. Takaki H, Yamakado K, Nakatsuka A, Yamada T, Uraki J, Kasahima M, et al. Computed tomography fluoroscopy-guided radiofrequency ablation following intra-arterial iodized-oil injection for hepatocellular carcinomas invisible on ultrasonographic images. Int J Clin Oncol 2013; 18: 46-53.

25. Laeske FF, Sampson LA, Haemmerich D, Brace CL, Fine JP, Frey TM, et al. Multiple-electrode radiofrequency ablation creates confluent areas of necrosis: in vivo porcine liver results. Radiology 2006; 241: 116-124.

26. Brace CL, Sampson LA, Hinshaw JL, Sandhu N, Lee FT Jr. Radiofrequency ablation: simultaneous application of multiple electrodes via switching creates larger, more confluent ablations than sequential application in a large animal model. J Vasc Interv Radiol 2009; 20: 118-124. doi: 10.1016/j.jvir.2008.09.021.

27. Takaki H, Yamakado K, Nakatsuka A, Fuke H, Murata K, Shiraki T, Kakeda K. Radiofrequency ablation combined with chemomobilization for the treatment of hepatocellular carcinomas 5 cm or smaller: risk factors for local tumor progression. J Vasc Interv Radiol 2007; 18: 856-861.

28. Woo S, Lee JM, Yoon JH, Joo I, Kim SH, Lee JY, et al. Small- and medium-sized hepatocellular carcinomas: monopolar radiofrequency ablation with a multiple-electrode switching system-mid-term results. Radiology 2013; 268: 589-600.

29. N’Kontchou G, Nault JC, Sutter O, Bourcier V, Coderc E, Grando F, Woo S, Lee JM, Yoon JH, Cho Y, Cho JS, Kim SH, et al. Major complications after radio-frequency thermal ablation of hepatic tumors: spectrum of imaging findings. RadioGraphics. 2003; 23: 123-134.

30. Ivraghi T, Solbiati L, Meloni MF, Gazelle GS, Halpern EF, Goldberg SN. Treatment of focal liver tumors with percutaneous radiofrequency ablation: complications encountered in a multicenter study. Radiology 2003; 226:441-451.

31. Fernandes DD1, Shyn PB, Silverman SG. Gallbladder needle decompression during radiofrequency ablation of an adjacent liver tumour. Can Assoc Radiol J 2012; 63: S37-S40. doi: 10.1016/j.carj.2011.05.003. Epub 2012 Jan 27.

32. Nishimura M, Kariyama K, Wakuta A, Tsuji H, Nanba J, Higashi T. Clinical study of radiofrequency ablation under biliary duct cooling via endoscopic Naso-biliary Drainage. Acta Hepatologica Japonica 2006; 47: 123-128.

33. Gannon J, Koch G, Caudrelier J, Ramamurthy N, Auloge P, Cazzato RL, et al. Hydrodissection of the gallbladder bed: a technique for ablations located close to the gallbladder. Cardiovasc Intervent Radiol 2019; 42: 1029-1035. doi: 10.1007/s00270-019-02218-5.

34. Campbell C, Lubner MG, Hinshaw JL, Munoz del Rio A, Brace CL. Contrast media-doped hydrodissection during thermal ablation: optimizing contrast media concentration for improved visibility on CT images. AJR. Am J Roentgenol 2012; 199: 677-682.

35. Hasegawa T, Takaki H, Miyagi H, Nakatsuka A, Uraki J, Yamanaka T, et al. Hyaluronic acid gel injection to prevent thermal injury on CT images. AJR. Am J Roentgenol 2012; 199: E142.

36. Giorgio A, Tarantino L, de Stefano G, Coppola C, Ferriailo G. Complications after percutaneous saline-enhanced radiofrequency ablation of liver tumors: 3-year experience with 336 patients at a single center. AJR 2005; 184: 207-211.

37. Tateishi R, Shinya S, Teratani T, Ohi S, Sato S, Koike Y, et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma: an analysis of 1000 cases. Cancer 2005; 103: 1201-1209.

38. Buscarini E, Buscarini L. Radiofrequency thermal ablation with expandable needle of focal liver malignancies: complication report. Eur Radiol 2004; 14: 31-37.

39. de Baer T, Risse O, Kuoch V, Dromain C, Sengel C, Smayra T, et al. Major complications after radio-frequency thermal ablation of hepatic tumors. AJR 2003; 181: 695-700.

40. Rhim H, Yoon KH, Lee JM, Cho Y, Cho JS, Kim SH, et al. Major complications after radio-frequency thermal ablation of hepatic tumors: spectrum of imaging findings. RadioGraphics. 2003; 23: 123-134.

41. Paik YK, Lee SB, Yoon HS, et al. Hydrodissection and preclinical experiments to clinical trials. Diagn Interv Imaging 2011. doi: 10.1016/S1470-2045(11)00198-9.

42. Fernandes DD1, Shyn PB, Silverman SG. Gallbladder needle decompression during radiofrequency ablation of an adjacent liver tumour. Can Assoc Radiol J 2012; 63: S37-S40. doi: 10.1016/j.carj.2011.05.003. Epub 2012 Jan 27.

43. Nishimura M, Kariyama K, Wakuta A, Tsuji H, Nanba J, Higashi T. Clinical study of radiofrequency ablation under biliary duct cooling via endoscopic Naso-biliary Drainage. Acta Hepatologica Japonica 2006; 47: 123-128.

44. Gannon J, Koch G, Caudrelier J, Ramamurthy N, Auloge P, Cazzato RL, et al. Hydrodissection of the gallbladder bed: a technique for ablations located close to the gallbladder. Cardiovasc Intervent Radiol 2019; 42: 1029-1035. doi: 10.1007/s00270-019-02218-5.

45. Campbell C, Lubner MG, Hinshaw JL, Munoz del Rio A, Brace CL. Contrast media-doped hydrodissection during thermal ablation: optimizing contrast media concentration for improved visibility on CT images. AJR. Am J Roentgenol 2012; 199: 677-682.

46. Hasegawa T, Takaki H, Miyagi H, Nakatsuka A, Uraki J, Yamanaka T, et al. Hyaluronic acid gel injection to prevent thermal injury of adjacent gastrointestinal tract during percutaneous liver radiofrequency ablation. Cardiovasc Interv Radiol 2013; 36: 1144-1146.

47. Gannon J, Koch G, Caudrelier J, Boatta E, Rao P, Nouri-Neuville M, et al. Hydrodissection of the retrohepatic space: a technique to physically separate a liver Tumour from the inferior vena cava and the stta of the hepatic veins. Cardiovasc Intervent Radiol 2019; 42: 137-144. doi: 10.1007/s00270-018-2105-y.

48. Yamakado K, Nakatsuka A, Akeboshi M, Takeda K. Percutaneous radiofrequency ablation of liver neoplasms adjacent to the gastrointestinal tract after balloon catheter interposition. J Vasc Interv Radiol 2003; 14: 1183-1186.

49. Goto E, Tateishi R, Shinya S, Masuzaki R, Enooku K, Sato T, et al. Hemorrhagic complications of percutaneous radiofrequency ablation for liver tumors. J Clin Gastroenterol 2010; 44: 374-380.

50. Hasegawa T, Inaba Y, Takahashi M, Chatani S, Dejima I, Tsukamoto H, et al. Pseudoaneurysm formation and hemobilia as late complications after transarterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma. Gastrointest Interv 2019; 4: 32-35.